1. European Medicines Agency (2004) Position paper on non-clinical safety studies to support clinical trials with a single microdose. European Medicines Agency. ( http://www.emea.europa.eu/pdfs/human/swp/259902en.pdf )
2. Food and Drug Administration (2004) Innovation or stagnation: challenges and opportunity on the critical path to new medical products. US Department of Health and Human Services. ( http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html )
3. Food and Drug Administration (2006) Guidance for industry, investigators, and reviewers: Exploratory IND studies. US Department of Health and Human Services. ( http://www.fda.gov/CDER/guidance/7086fnl.htm )
4. Food and Drug Administration (2006) Guidance for Industry: INDs—approaches to complying with CGMP during Phase 1 (draft guidance). US Department of Health and Human Services. ( http://www.fda.gov/CDER/guidance/6164dft.htm )
5. Gutierrez M, Kummar S, Horneffer Y, Juwara L, Chen A, Melillo G, Pickeral O, Tomaszewski J, Murgo AJ, Doroshow JH, Group NPW (2007) Recruitment experience in a Phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerse (PARP), in patients (pts) with advanced malignancies. J Clin Oncol 25:14111